MaaT Pharma S.A.
MAAT.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | -0.18 | -0.21 | -0.06 |
| FCF Yield | -21.47% | -8.99% | -14.11% | -7.67% |
| EV / EBITDA | -4.91 | -6.50 | -6.03 | -6.26 |
| Quality | ||||
| ROIC | -41.69% | -58.04% | -26.16% | -32.78% |
| Gross Margin | 67.45% | -5.08% | 68.80% | 30.12% |
| Cash Conversion Ratio | 1.02 | 0.59 | 0.98 | 0.50 |
| Growth | ||||
| Revenue 3-Year CAGR | 147.23% | 293.56% | 64.21% | 55.05% |
| Free Cash Flow Growth | -55.69% | 21.44% | -105.12% | 54.19% |
| Safety | ||||
| Net Debt / EBITDA | 0.04 | 0.25 | 1.11 | 0.90 |
| Interest Coverage | -34.95 | -28.52 | -48.69 | -22.46 |
| Efficiency | ||||
| Inventory Turnover | 8.88 | 24.55 | 3.00 | 3.13 |
| Cash Conversion Cycle | -472.22 | -410.87 | -544.33 | -386.41 |